[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gynaecologic-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gynaecologic-cancer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,77,103,129,165],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100608410","holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea-100608410",false,"NCT07201194","Holistic Acupuncture for Patients With Chemotherapy Induced Nausea","HOL-AKU: Holistic Acupuncture for Patients With Chemotherapy Induced Nausea","Inclusion criteria\n\n* ≥ 18 years of age\n* Undergoing chemotherapy and experiencing nausea despite adherence to the prescribed antiemetic regimen\n* Understands and speaks Danish\n* Written and orally informed consent\n* Planned for treatment every 14 days\n* At least two chemotherapy cycles planned at the time of inclusion\n\nExclusion Criteria:\n\n* Brain metastases\n* Performance status \\>2","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"NA","The study explores whether acupuncture as a supplement to conventional antiemetic medicine is superior in reducing the level of chemotherapy induced nausea compared to conventional anitemetic medicine alone.\n\nA total of 90 patients experiencing chemotherapy induced nausea will be allocated 1:1 to either acupuncture and antiemetic medicine or antiemetic medicine alone.\n\nThe level of nausea and other cancer related symptoms will be assessed at baseline and 8 and 22 days after enrollment",[26,27,28,29,30,31],"Breast Cancer","Prostate Cancer","Lung Cancer","Gynaecologic Cancer","Colorectal Cancer","Pancreatic Cancer Metastatic",[33,34],"acupuncture","chemotherapy induced nauseau","RECRUITING","2026-05-27",{"date":38,"type":39},"2026-05-28","ACTUAL",{"date":41,"type":39},"2025-11-17",{"date":43,"type":20},"2027-12-31",{"name":45,"class":46},"Vejle Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100630625","benefits-of-early-collaboration-between-oncologists-and-palliative-care-physicians-in-cases-of-unplanned-hospitalization-for-patients-with-metastatic-cancer-100630625","NCT07490106","Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer","SPPC","Inclusion Criteria:\n\n* Subjects aged 18 years and older;\n* Diagnosed with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer;\n* Currently undergoing systemic palliative treatment (no prospect of cure);\n* Hospitalized on an unscheduled basis (i.e., unplanned hospitalization for scheduled oncology treatments);\n* Patient covered by the French social security system;\n* Informed consent, written and signed.\n\nExclusion Criteria:\n\n* PS (WHO) = 4;\n* Patient receiving end-of-life care;\n* Patient opposed to the use of medical data for research purposes;\n* Person deprived of liberty or under guardianship;\n* Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.",{"count":56,"type":20},493,[23],"This is a multicenter, national, interventional, cluster-randomized study, \"stepped wedge\" design. This study includes patients with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer, currently undergoing systemic palliative treatment and hospitalized on an unscheduled basis. The study will aim to evaluate the impact of early palliative care implementation for patients with metastatic or advanced cancer identified during an unplanned hospitalization.",[60,61,29,62,63,64],"Cancer","Sarcoma Metastatic","Digestive Cancers","ENT Cancer","Metastatic Cancer or Locally Advanced",[66],"Metastatic or Locally Advanced digestive, gynecological, ENT, or sarcoma cancer","NOT_YET_RECRUITING","2026-03-19",{"date":70,"type":39},"2026-03-24",{"date":72,"type":20},"2026-04",{"date":74,"type":20},"2031-04",{"name":76,"class":46},"Centre Oscar Lambret",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100624903","phase-2-gccc-2578-randomized-photon-vs-proton-rt-for-newly-diagnosed-gynecologic-primaries-100624903","NCT07415681","GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","A Phase II, Randomized, Open-Label, Single-Center Study Comparing Intensity Modulated Proton Therapy Versus Volume Modulated Arc Therapy in Patients Receiving Pelvic Nodal Irradiation for Newly Diagnosed Gynecologic Primaries","Inclusion Criteria:\n\n1. a. Newly diagnosed endometrial cancer after TAH\u002FBSO and nodal sampling, sentinel LN biopsy or pelvic nodal dissection planning to receive sequential chemotherapy and radiation or concurrent chemoradiotherapy or b. cervical cancer planning to receive definitive chemoradiation with HDR brachytherapy boost\n2. Histologic confirmation of malignancy (primary only)\n3. ≥ 18 years of age\n4. ECOG performance status ≤ 2\n5. Patient must have the ability to understand and the willingness to sign a written informed consent document or when appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf.\n6. Insurance approval for IMPT\n\nExclusion Criteria:\n\n1. Metastatic disease beyond para-aortic lymph nodal region\n2. Residual tumor after surgery exceeding 2 cm in maximum dimension in patients with endometrial cancer.\n3. FIGO 2014 stage III-IVA cervix cancer planning to receive concurrent pembrolizumab.\n4. Cervical cancer with inability to receive concurrent chemotherapy.\n5. Any prior pelvic radiation.\n6. Treatment with other investigational agents.\n7. Carcinosarcoma.\n8. Creatine clearance \\\u003C30 mL\u002Fm2\n9. Unable to lie flat during or tolerate radiation.\n10. Refusal to sign informed consent.\n11. Any additional active cancer that would interfere with the primary study endpoints","FEMALE",{"count":86,"type":20},116,[88],"PHASE2","The purpose of study is to compare the side effects of two different forms of radiation for endometrial and cervical cancer. If you decide to enroll in this study, you will be randomized to one of two treatment groups. This study will compare two standard of care treatments: \"Conventional\" pHoton radiation versus pRoton radiation.",[29,91,92],"Cervical Cancer","Radiation Therapy","2026-02-09",{"date":95,"type":39},"2026-02-17",{"date":97,"type":20},"2026-03",{"date":99,"type":20},"2033-12",{"name":101,"class":46},"University of Maryland, Baltimore",5,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100611050","more-representative-vaginal-temperature-measurements-with-a-hyperthermia-pelotte-during-hyperthermia-treatments-for-gynaecological-cancer-100611050","NCT07235540","More Representative Vaginal Temperature Measurements With a Hyperthermia Pelotte During Hyperthermia Treatments for Gynaecological Cancer.","The Use of a Hyperthermia Pelotte to Acquire More Representative Vaginal Temperature Measurements During Deep Hyperthermia Treatments for Gynaecological Cancer; a Comparative Cross-over Study.","ORIENTATE","Inclusion Criteria:\n\n* Women aged 18 or older diagnosed with gynaecological cancer\n* Indication for EBRT with DHT\n* Written informed consent\n\nExclusion Criteria:\n\n* Any condition potentially interfering with the understanding of the study requirements, informed consent procedure and completion of questionnaires\n* If the vaginal lumen is \\\u003C4 cm.",{"count":112,"type":20},27,[23],"The goal of this comparative, cross over single centre study is to to determine whether the average measured vaginal temperature during hyperthermia treatment is (clinically) significant different with the use of a pelotte than with a standard vaginal probe. in 27 women treated with external beam radiotherapy and deep hyperthermie for gynaecological cancer.. The primary endpoint is measured average vaginal temperatures with pelotte versus a standard vaginal probe.\n\nThe secondary endpoints are: reproducibility of catheter placement, patient comfort, inter-fractional spread of the vaginal temperature and the average vaginal temperature at the tip (0 cm) and 2 cm from the tip with pelotte and a standard vaginal probe.\n\nParticipants will be treated at least two time with a pelotte and two times with a standard vaginal probe. Participants will be asked to fill in a short questionnaire three times per treatment (before, during and after treatment). A total of 12-15 questionnaires will be completed by the participants over the four to five treatments.",[29],[117,118,119,120],"Pelotte","Hyperthermia","Probe","Gynaecologic",{"date":122,"type":39},"2025-11-19",{"date":124,"type":20},"2026-01-05",{"date":126,"type":20},"2028-01-05",{"name":128,"class":46},"Dr. G.H. (Henrike) Westerveld",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":84,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":153,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":47},"100609100","pre-habilitation-within-eras-protocol-for-gynecologic-oncology-surgery-the-preeras-study-100609100","NCT07210164","Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study","Prehabilitation With Exercise and Immunonutrition (Ocoxin®) in the Perioperative Management of Gynecologic Malignancies Under ERAS Protocol.","Pre_ERAS","Inclusion Criteria:\n\n* Type of gynecological malignancy: endometrial cancer, ovarian cancer, cervical cancer, treated with laparotomy after the decision of the gynecological-oncology unit (positive opinion of the Multidisciplinary Tumor Board - MDT)\n* Patient age: 18 to 85 years\n* General condition of the patient: ASA score I-III\n* Consent to implement the accelerated recovery protocol - Enhanced recovery after surgery (ERAS)\n* Sufficient understanding of the Greek language\n* Provision of signed, after thorough information, consent to participate in the study\n\nExclusion Criteria:\n\n* Women with performance status: ECOG \\>2 and ASA score \\>III\n* Women who have not been informed and have given written consent","85 Years",{"count":139,"type":20},100,[23],"ERAS (Enhanced Recovery After Surgery) protocols are step-by-step care plans that help patients recover faster after surgery. They focus on keeping the body's normal functions, lowering stress from surgery, and supporting a quicker recovery. In gynecologic cancer surgeries, ERAS has been shown to help patients do better, have fewer problems, and leave the hospital sooner.\n\nA prehabilitation program, in combination with ERAS protocols, aims to optimize patients' physical and psychological condition prior to surgery for gynecological cancers. Interventions may include tailored exercise, nutritional support, respiratory training, and psychological preparation. By enhancing baseline fitness and resilience, prehabilitation improves the body's ability to tolerate surgical stress, reduces complications, and facilitates a faster, smoother recovery within the ERAS framework.",[143,144,145,146,147,148,149,150,151,29,152],"ERAS","Compliance","Quality of Life (QOL)","Excercise","Immunonutrition","Post Operative Pain","Laparotomy Patients","Surgical Complication","Gynaecological Malignancies","Gynaecological Oncology",[154,143,155,147],"Prehabilitation","Gynecologic Cancers","2025-09-29",{"date":158,"type":39},"2025-10-07",{"date":160,"type":20},"2025-12-01",{"date":162,"type":20},"2029-12-30",{"name":164,"class":46},"Aristotle University Of Thessaloniki",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":84,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":21,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100604057","improving-sexual-health-in-gynecological-cancer-patients-100604057","NCT07144566","Improving Sexual Health in Gynecological Cancer Patients","Implementation of a Nurse-Led Clinical Program to Decrease Sexual Dysfunction Among Gynecological Cancer Patient","Inclusion:\n\n* Patients with a gynecologic cancer history\n* Patients ages 30-65 years old\n* Patients must have completed cancer treatment within the past 12 months\n* Patients may be on maintenance therapy\n\nExclusion:\n\n* Any records flagged \"break the glass\" or \"research opt-out.\"\n* Patients with severe psychiatric disorders that would impair consent or participation\n* Patients with neurological disorders affecting sexual function\n* Patients with a history of sexual violence or sexual assault","30 Years","65 Years",{"count":175,"type":20},35,[23],"The goal of this clinical trial is to test whether a nurse-led program can improve screening and referral rates for sexual dysfunction and improve sexual health care in individuals with gynecological cancer. The main questions it aims to answer are:\n\nDoes participation in a nurse-led program improve the treatment of sexual dysfunction in individuals with gynecological cancer?\n\nDoes the program increase the frequency of screenings and referrals for sexual dysfunction?\n\nParticipants will:\n\nComplete a visit with an advanced practice provider.\n\nFill out the Female Sexual Function Index survey.\n\nAllow the research team to review medical records.",[29],[180,181,182,183],"Survivorship","Sexual Health","Sexual Dysfunction","Gynecologic Cancer","2025-08-25",{"date":186,"type":39},"2025-08-27",{"date":188,"type":20},"2025-09-02",{"date":190,"type":20},"2026-04-30",{"name":192,"class":46},"Cedars-Sinai Medical Center"]